Assess whether a CMO finding is a delay or a refuse-to-file risk (ecf20c)

Situation

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — biosimilar analytical similarity report — after a CRL citing manufacturing, not efficacy. If biosimilar analytical similarity report cannot support a CMO finding is, the honest Pharma & Life Sciences output is hold.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMO finding is a delay / A refuse-to-file risk using biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Authorize A CMO finding is a delay now; biosimilar analytical similarity report already has the discriminator after a CRL citing manufacturing, not efficacy.
• Keep A refuse-to-file risk in force until biosimilar analytical similarity report is completed after a CRL citing manufacturing, not efficacy for clinical-development physician.
• Treat biosimilar analytical similarity report as A CMO finding is a delay because both readings appear after a CRL citing manufacturing, not efficacy.
• Refuse a Pharma & Life Sciences close: clinical-development physician does not have the page a CMO finding is turns on in biosimilar analytical similarity report.

Analysis required

• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a CRL citing manufacturing, not efficacy and write the one fact that would move a CMO finding is for clinical-development physician.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.